These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 9284856)

  • 1. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
    Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
    Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
    N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
    Ogihara T; Rakugi H; Ikegami H; Mikami H; Masuo K
    Am J Hypertens; 1995 Mar; 8(3):316-20. PubMed ID: 7794582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
    N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
    Tack CJ; Ong MK; Lutterman JA; Smits P
    Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of troglitazone on insulin sensitivity.
    Henry RR
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
    Varo N; Vicent D; Libby P; Nuzzo R; Calle-Pascual AL; Bernal MR; Fernández-Cruz A; Veves A; Jarolim P; Varo JJ; Goldfine A; Horton E; Schönbeck U
    Circulation; 2003 Jun; 107(21):2664-9. PubMed ID: 12742991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone in type II diabetes mellitus.
    Sparano N; Seaton TL
    Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.